Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

Advances in the understanding of the molecular basis for acute myeloid leukemia (AML) have generated new potential targets for treatment. Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML and mutations in this gene are associated with poor overall survival. AXL pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Masamichi, Kaneko, Naoki, Ueno, Yoko, Yamada, Masaki, Tanaka, Ruriko, Saito, Rika, Shimada, Itsuro, Mori, Kenichi, Kuromitsu, Sadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Preclinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613053/
https://www.ncbi.nlm.nih.gov/pubmed/28516360
http://dx.doi.org/10.1007/s10637-017-0470-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613053/
https://www.ncbi.nlm.nih.gov/pubmed/28516360
http://dx.doi.org/10.1007/s10637-017-0470-z

Ejemplares similares